Hikma Pharmaceuticals PLC

LSE:HIK Rapport sur les actions

Capitalisation boursière : UK£4.2b

Hikma Pharmaceuticals Croissance future

Future contrôle des critères 2/6

Hikma Pharmaceuticals devrait augmenter ses bénéfices et son chiffre d'affaires de 12.8% et de 3.8% par an respectivement. Le BPA devrait croître de de 15.9% par an. Le rendement des capitaux propres devrait être 18.1% dans 3 ans.

Informations clés

12.8%

Taux de croissance des bénéfices

15.9%

Taux de croissance du BPA

Pharmaceuticals croissance des bénéfices19.3%
Taux de croissance des recettes3.8%
Rendement futur des capitaux propres18.1%
Couverture par les analystes

Good

Dernière mise à jour18 Nov 2024

Mises à jour récentes de la croissance future

Hikma Pharmaceuticals PLC Beat Analyst Estimates: See What The Consensus Is Forecasting For This Year

Aug 11
Hikma Pharmaceuticals PLC Beat Analyst Estimates: See What The Consensus Is Forecasting For This Year

Recent updates

Hikma Pharmaceuticals PLC's (LON:HIK) P/E Is On The Mark

Nov 11
Hikma Pharmaceuticals PLC's (LON:HIK) P/E Is On The Mark

Does Hikma Pharmaceuticals (LON:HIK) Have A Healthy Balance Sheet?

Oct 24
Does Hikma Pharmaceuticals (LON:HIK) Have A Healthy Balance Sheet?

Hikma Pharmaceuticals PLC Beat Analyst Estimates: See What The Consensus Is Forecasting For This Year

Aug 11
Hikma Pharmaceuticals PLC Beat Analyst Estimates: See What The Consensus Is Forecasting For This Year

Hikma Pharmaceuticals PLC (LON:HIK) Shares Could Be 36% Below Their Intrinsic Value Estimate

Aug 01
Hikma Pharmaceuticals PLC (LON:HIK) Shares Could Be 36% Below Their Intrinsic Value Estimate

Is Hikma Pharmaceuticals PLC (LON:HIK) Trading At A 29% Discount?

Apr 24
Is Hikma Pharmaceuticals PLC (LON:HIK) Trading At A 29% Discount?

Is Hikma Pharmaceuticals (LON:HIK) A Risky Investment?

Apr 02
Is Hikma Pharmaceuticals (LON:HIK) A Risky Investment?

Hikma Pharmaceuticals PLC's (LON:HIK) Share Price Matching Investor Opinion

Feb 25
Hikma Pharmaceuticals PLC's (LON:HIK) Share Price Matching Investor Opinion

Does Hikma Pharmaceuticals (LON:HIK) Have A Healthy Balance Sheet?

Dec 27
Does Hikma Pharmaceuticals (LON:HIK) Have A Healthy Balance Sheet?

An Intrinsic Calculation For Hikma Pharmaceuticals PLC (LON:HIK) Suggests It's 43% Undervalued

Dec 12
An Intrinsic Calculation For Hikma Pharmaceuticals PLC (LON:HIK) Suggests It's 43% Undervalued

Hikma Pharmaceuticals (LON:HIK) Has A Pretty Healthy Balance Sheet

Sep 19
Hikma Pharmaceuticals (LON:HIK) Has A Pretty Healthy Balance Sheet

Calculating The Intrinsic Value Of Hikma Pharmaceuticals PLC (LON:HIK)

Sep 01
Calculating The Intrinsic Value Of Hikma Pharmaceuticals PLC (LON:HIK)

Is Hikma Pharmaceuticals (LON:HIK) A Risky Investment?

Jun 21
Is Hikma Pharmaceuticals (LON:HIK) A Risky Investment?

Hikma Pharmaceuticals PLC's (LON:HIK) Intrinsic Value Is Potentially 28% Above Its Share Price

Jun 02
Hikma Pharmaceuticals PLC's (LON:HIK) Intrinsic Value Is Potentially 28% Above Its Share Price

Hikma Pharmaceuticals (LON:HIK) Has A Pretty Healthy Balance Sheet

Mar 14
Hikma Pharmaceuticals (LON:HIK) Has A Pretty Healthy Balance Sheet

Calculating The Intrinsic Value Of Hikma Pharmaceuticals PLC (LON:HIK)

Feb 21
Calculating The Intrinsic Value Of Hikma Pharmaceuticals PLC (LON:HIK)

Does Hikma Pharmaceuticals (LON:HIK) Have A Healthy Balance Sheet?

Sep 27
Does Hikma Pharmaceuticals (LON:HIK) Have A Healthy Balance Sheet?

Hikma Pharmaceuticals PLC's (LON:HIK) Intrinsic Value Is Potentially 19% Below Its Share Price

Jun 24
Hikma Pharmaceuticals PLC's (LON:HIK) Intrinsic Value Is Potentially 19% Below Its Share Price

These 4 Measures Indicate That Hikma Pharmaceuticals (LON:HIK) Is Using Debt Reasonably Well

Jun 06
These 4 Measures Indicate That Hikma Pharmaceuticals (LON:HIK) Is Using Debt Reasonably Well

Here's Why Hikma Pharmaceuticals (LON:HIK) Can Manage Its Debt Responsibly

Feb 26
Here's Why Hikma Pharmaceuticals (LON:HIK) Can Manage Its Debt Responsibly

Hikma Pharmaceuticals PLC's (LON:HIK) Intrinsic Value Is Potentially 92% Above Its Share Price

Dec 01
Hikma Pharmaceuticals PLC's (LON:HIK) Intrinsic Value Is Potentially 92% Above Its Share Price

Is Hikma Pharmaceuticals (LON:HIK) Using Too Much Debt?

Nov 11
Is Hikma Pharmaceuticals (LON:HIK) Using Too Much Debt?

Is There An Opportunity With Hikma Pharmaceuticals PLC's (LON:HIK) 32% Undervaluation?

Sep 02
Is There An Opportunity With Hikma Pharmaceuticals PLC's (LON:HIK) 32% Undervaluation?

Is Hikma Pharmaceuticals (LON:HIK) A Risky Investment?

Aug 09
Is Hikma Pharmaceuticals (LON:HIK) A Risky Investment?

Hikma Pharmaceuticals PLC (LON:HIK) Shares Could Be 26% Below Their Intrinsic Value Estimate

May 21
Hikma Pharmaceuticals PLC (LON:HIK) Shares Could Be 26% Below Their Intrinsic Value Estimate

Hikma Pharmaceuticals (LON:HIK) Seems To Use Debt Quite Sensibly

May 03
Hikma Pharmaceuticals (LON:HIK) Seems To Use Debt Quite Sensibly

It's Unlikely That Hikma Pharmaceuticals PLC's (LON:HIK) CEO Will See A Huge Pay Rise This Year

Apr 16
It's Unlikely That Hikma Pharmaceuticals PLC's (LON:HIK) CEO Will See A Huge Pay Rise This Year

How Does Hikma Pharmaceuticals PLC (LON:HIK) Stand Up To These Simple Dividend Safety Checks?

Apr 13
How Does Hikma Pharmaceuticals PLC (LON:HIK) Stand Up To These Simple Dividend Safety Checks?

Hikma Pharmaceuticals PLC (LON:HIK) Looks Interesting, And It's About To Pay A Dividend

Mar 14
Hikma Pharmaceuticals PLC (LON:HIK) Looks Interesting, And It's About To Pay A Dividend

Hikma Pharmaceuticals PLC Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Predictions

Feb 28
Hikma Pharmaceuticals PLC Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Predictions

Prévisions de croissance des bénéfices et des revenus

LSE:HIK - Estimations futures des analystes et données financières antérieures (USD Millions )
DateRecettesLes revenusFlux de trésorerie disponibleCash from OpMoy. Nombre d'analystes
12/31/20263,3205235428178
12/31/20253,1774795177758
12/31/20243,0394433525528
6/30/20243,017285379584N/A
3/31/20242,946238392596N/A
12/31/20232,875190404608N/A
9/30/20232,803168389596N/A
6/30/20232,731146373583N/A
3/31/20232,624167344557N/A
12/31/20222,517188314530N/A
9/30/20222,534267325557N/A
6/30/20222,550346335583N/A
3/31/20222,552384372611N/A
12/31/20212,553421409638N/A
9/30/20212,489444294517N/A
6/30/20212,425467179396N/A
3/31/20212,383449210430N/A
12/31/20202,341431240464N/A
9/30/20202,317472306521N/A
6/30/20202,292513372577N/A
3/31/20202,250500329525N/A
12/31/20192,207486286472N/A
9/30/20192,173424283452N/A
6/30/20192,138361279432N/A
3/31/20192,104322285431N/A
12/31/20182,070282291430N/A
9/30/20182,045-262275417N/A
6/30/20182,020-806259403N/A
3/31/20181,978-824N/A423N/A
12/31/20171,936-843N/A443N/A
9/30/20171,950-338N/A431N/A
6/30/20171,963166N/A419N/A
3/31/20171,957161N/A356N/A
12/31/20161,950155N/A293N/A
9/30/20161,782166N/A317N/A
6/30/20161,613176N/A340N/A
3/31/20161,527214N/A353N/A
12/31/20151,440252N/A366N/A
9/30/20151,450248N/A358N/A
6/30/20151,460243N/A350N/A
3/31/20151,475261N/A388N/A
12/31/20141,489278N/A425N/A
9/30/20141,477293N/A413N/A
6/30/20141,465308N/A401N/A
3/31/20141,415260N/A369N/A
12/31/20131,365212N/A337N/A

Prévisions de croissance des analystes

Taux de revenus par rapport au taux d'épargne: La croissance des bénéfices prévue de HIK ( 12.8% par an) est supérieure au taux d'épargne ( 2.1% ).

Bénéfices vs marché: Les bénéfices de HIK ( 12.8% par an) devraient croître plus lentement que le marché UK ( 14.6% par an).

Croissance élevée des bénéfices: Les bénéfices de HIK devraient augmenter, mais pas de manière significative.

Chiffre d'affaires vs marché: Le chiffre d'affaires de HIK ( 3.8% par an) devrait croître plus rapidement que le marché UK ( 3.5% par an).

Croissance élevée des revenus: Le chiffre d'affaires de HIK ( 3.8% par an) devrait croître plus lentement que 20% par an.

Prévisions de croissance du bénéfice par action

Rendement futur des capitaux propres

ROE futur: Le retour sur capitaux propres de HIK devrait être faible dans 3 ans ( 18.1 %).

Découvrir les entreprises en croissance

7D

1Y

7D

1Y

7D

1Y